Impact of intraoperative intravenous magnesium on spine surgery: A systematic review and meta-analysis of randomized controlled trials.
Lei Yue, Zeng-Mao Lin, Guan-Zhang Mu...
https://pubmed.ncbi.nlm.nih.gov/35028543/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-08-21
40
Participants Needed
1
Research Sites
N/A
Total Duration
Spinal surgeries are becoming more frequent and complex, carrying risks of injury to neural structures. Intraoperative neurophysiologic monitoring IONM helps detect changes in motor and sensory pathways during surgery to improve safety. This trial evaluates how magnesium, a commonly used anesthetic adjunct to reduce pain and opioid use, affects Transcranial Motor Evoked Potentials TcMEPs, which monitor motor pathway integrity during spinal surgery. Despite widespread use, there is limited clinical data on magnesiums impact on these neuromonitoring signals. Participants will undergo standard general anesthesia with propofol and remifentanil, and all will have neuromonitoring equipment placed as usual. The experimental group receives a single intravenous bolus of magnesium sulfate at 30 mgkg over 10 minutes, while the control group follows the same protocol without magnesium. Blood samples will be collected at multiple time points up to 12 hours after magnesium administration to measure plasma levels and pharmacokinetics. The study aims to establish a protocol to quantify magnesiums effects on TcMEPs, providing data to guide safer anesthetic adjunct use. During surgery, baseline motor-evoked potential data will be collected, followed by magnesium administration in the experimental group. Researchers will monitor neuromonitoring data, including stimulation voltage, MEP amplitude, and latency, throughout the procedure. Blood tests for magnesium levels will be performed at scheduled intervals. Participants are adults undergoing elective thoracolumbar fusion with planned neuromonitoring. The study does not extend anesthesia time or add extra monitoring procedures beyond standard care. Outcome measures include magnesium pharmacokinetics and neuromonitoring changes over about one year of study completion.
CONDITIONS
Effect of Magnesium on Neuromonitoring
H
Hemra Cil, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Magnesium sulfate administration (single bolus, 30 mg/kg IV) | Standard care without magnesium administration |
|---|---|---|
| What it is | IV magnesium sulfate (30 mg/kg, one bolus) is administered over 10 minutes to patients before neuromonitoring in spine fusion surgery. | No magnesium is given; patients undergo spine fusion with routine perioperative neuromonitoring. |
| Role in trial | Serves as the experimental group evaluating magnesium's effect on motor-evoked potentials and pharmacokinetics. | Serves as the control group for neuromonitoring without magnesium administration. |
| Primary use | Used to study how magnesium sulfate alters neuromonitoring signals and pharmacokinetic measures in spine surgery. | Represents routine neuromonitoring without magnesium; used to establish baseline and compare magnesium effects. |
| How it is given or performed | Single intravenous bolus of magnesium sulfate (30 mg/kg, ideal body weight) administered over 10 minutes, before surgical neuromonitoring begins. | No magnesium is administered; standard anesthesia and neuromonitoring procedures are followed throughout surgery. |
| Evidence status | Systematic reviews and laboratory studies show magnesium sulfate may alter motor evoked potential amplitude and latency during spine surgery, but effects are variable and clinical relevance remains incompletely established. | Routine neuromonitoring without magnesium is well established in perioperative spine surgery and serves as the baseline for evaluating neuromonitoring changes. |
| Important limitations | Potential for magnesium to alter neuromonitoring signals may complicate surgical interpretation; trial sample size is modest and effects may differ based on anesthesia and comorbidities. | Standard neuromonitoring is subject to limitations from patient variability, anesthetic effects, and technical monitoring challenges; results may not generalize to all types of spine surgery. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - During surgery
Participants receive general anesthesia with propofol and remifentanil, with or without a single intravenous magnesium bolus during surgery. Neuromonitoring equipment is used to monitor motor pathways throughout the procedure.
Continuous monitoring during surgery
Duration - 12 hours after surgery
Blood samples are collected at multiple time points up to 12 hours after magnesium administration to measure magnesium plasma levels and pharmacokinetics. Neuromonitoring data is also recorded.
Multiple blood draws during recovery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lei Yue, Zeng-Mao Lin, Guan-Zhang Mu...
https://pubmed.ncbi.nlm.nih.gov/35028543/Kenta Furutani, Hiroyuki Deguchi, Mari Matsuhashi...
https://pubmed.ncbi.nlm.nih.gov/31633576/M R Tramer, J Schneider, R A Marti...
https://pubmed.ncbi.nlm.nih.gov/8602664/Tucker Johnson, Emily B Kale, Aatif M Husain
https://pubmed.ncbi.nlm.nih.gov/29923809/Tod B Sloan, Eric J Heyer
https://pubmed.ncbi.nlm.nih.gov/12477988/Hong Wang, Qi-sheng Liang, Lan-ren Cheng...
https://pubmed.ncbi.nlm.nih.gov/21986576/Samuel N Blacker, Anita Vincent, Mark Burbridge...
https://pubmed.ncbi.nlm.nih.gov/34483301/J Herdmann, V Deletis, H L Edmonds...
https://pubmed.ncbi.nlm.nih.gov/8779023/D B Macdonald, S Skinner, J Shils...
https://pubmed.ncbi.nlm.nih.gov/24055297/Bridget A Martell, Julia H Arnsten, Mori J Krantz...
https://pubmed.ncbi.nlm.nih.gov/15781034/University of California, San Francisco
Lead Sponsor